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Acute myeloid leukemia (AML) is a genetically heterogeneous disease. Certain cytogenetic and molecular genetic mutations are
recognized to have an impact on prognosis, leading to their inclusion in some prognostic stratification systems. Recently, the advent
of high-throughput whole genome or exome sequencing has led to the identification of several novel recurrent mutations in AML,
a number of which have been found to involve genes concerned with epigenetic regulation. These genes include in particular
DNMT3A, TET2, and IDH1/2, involved with regulation of DNA methylation, and EZH2 and ASXL-1, which are implicated in
regulation of histones. However, the precise mechanisms linking these genes to AML pathogenesis have yet to be fully elucidated
as has their respective prognostic relevance. As massively parallel DNA sequencing becomes increasingly accessible for patients,
there is a need for clarification of the clinical implications of these mutations. This review examines the literature surrounding the
biology of these epigenetic modifying genes with regard to leukemogenesis and their clinical and prognostic relevance in AML
when mutated.
1. Introduction
Acute myeloid leukemia (AML) is a genetically heteroge-
neous disease characterized bymalignant clonal proliferation
of immature myeloid cells in the bone marrow, peripheral
blood, and occasionally other body tissues [1, 2]. It is the
most common acute leukemia in adults and encompasses
15–20% of cases in children [2]. While the disease is most
commonly found in individuals over 60 years, AML also
occurs in younger people and occasionally may even be
present at birth [1, 2]. Environmental factors that increase the
risk of developing AML include smoking, benzene exposure,
and chemotherapy or radiotherapy treatment [1, 2]. Preced-
ing myelodysplastic syndrome (MDS) or myeloproliferative
neoplasm (MPN) may also develop into AML [3]. Although
highly variable, the outlook formost AML subtypes is dismal,
with an overall 5-year survival rate of approximately 25%
[1]. The genetic and epigenetic profile of the malignant cells
influences the likelihood of achieving remission and risk
of relapse [4]. A greater understanding of the underlying
genetic and epigenetic processes may provide insight into the
mechanism of leukemogenesis in AML, as well as offering
prognostic information and potential therapeutic targets.
The prognostic implications of many molecular mutations in
AML are well reported [5]. However, the role of mutations
in genes with epigenetic function is less clearly understood
[6–8]. This literature review, therefore, aims to examine the
pathological role and prognostic implications of mutations in
epigenetic modifying genes.
2. Genetics and Risk Stratification in AML
Many patients with AML will have cytogenetic aberrations
which can be detected through karyotyping or fluorescent
in situ hybridization (FISH) [9–11]. Risk stratification—into
low, intermediate, or high risk groups—can then be carried
out according to the cytogenetic profile of the patient [9, 10].
However, there is variation between different cooperative
groups as to the correct stratification of different mutations
[1]. Furthermore, nearly half of the patients have cytoge-
netically normal (CN) AML and are ascribed to the inter-
mediate risk category despite significant heterogeneity [5].
It is clear, therefore, that molecular mutational analysis has
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the potential to improve prognostication stratification sys-
tems. Currently, only a limited selection of genetic mutations
is included in widely used prognostic stratification models—
in the European LeukemiaNet (ELN) system, for exam-
ple, NPM1, FLT3-ITD, and CEBP𝛼 are the only molecular
mutations afforded prognostic significance [12]. The World
Health Organization has included a provisional entity in its
classification system which includes AML with NPM1 and
CEBP𝛼mutations [13]. Nonetheless, mutations which are not
included in stratification systemsmay still impact on progno-
sis. In addition, increasing access to whole genome or exome
mutational analysis techniques is yielding a bewildering array
of novel mutations associated with AML. Newly diagnosed
AML patients and their doctors are therefore likely to be
faced with a complex combination of different mutations,
with uncertain clinical significance, on genetic analysis.
3. The Two-Hit Hypothesis
For many years, the accepted model of leukemogenesis was
the “two-hit hypothesis,” which suggested that two different
types of genetic mutation were required for malignant trans-
formation of a myeloid precursor [8, 14]. Class I mutations
were thought to lead to uncontrolled cellular proliferation
and evasion of apoptosis and included mutations conferring
constitutive activity to tyrosine kinases or dysregulation of
downstream signalingmolecules (in genes such as BCR-ABL,
Flt-3, c-KIT, and RAS) [8, 14]. Class II mutations, such as the
translocations associated with the core-binding factor (CBF)
leukemias, were associated with inhibition of differentiation
including key transcription factors, such as CBF and retinoic
acid receptor alpha (RAR𝛼) [8, 14], and proteins that are
involved in transcriptional regulation, such as p300, CBP,
MOX, TIF2, and MLL [8, 14].
This hypothesis is supported by the observation that
a single mutation alone does not appear to be adequate
to engender acute leukemic transformation. Leukemia-
associated genetic aberrations (such as CBF translocations)
can be found in peripheral and cord blood in a proportion of
healthy individuals [15, 16]. Similarly, inducedCBFmutations
in murine models are not sufficient to induce malignant
transformation, despite resulting in increased self-renewal
capacity and reduced differentiation [17]. Mice with CBF
mutations have been found to only develop a leukemic syn-
drome when exposed to a further mutagen [18]. Additionally,
rare familial leukemia syndromes, involving CEBP𝛼 and
RUNX1 mutations, increase the risk of developing AML but
do not guarantee it [1, 19]. The fact that many AML patients
have more than one mutation in their leukemic cells also
indicates that in many cases there must be more than one
genetic “hit” required for leukemia to develop [20]. Kelly
and Gilliland, in 2002, proposed that Class I mutations,
occurring alone, would result in myeloproliferative diseases,
such as chronic myeloid leukemia, while isolated Class II
mutations may lead to the development of myelodysplastic
syndromes [14]. It is likely, therefore, that the increased risk of
development of AML in patients with either MPN or MDS is
JAK2
Class I
KIT
FLT3
N-RAS, K-RAS
PTPN11
Epigenetic
DNMT3A
TET2
EZH2
IDH1/2
ASXL1
WT1
Class II
CBF𝛽-MYH11
PML-RAR𝛼
RUNX1-RUNX1T1
RUNX1
NPM1 CEBP𝛼
EVI1
MLL 
translocations
MLL-PTD
Figure 1: This Venn diagram highlights some of the key mutations
found in AML and suggests classes to which these mutations could
be ascribed.
related to the accrual of further mutations of a different class
to those already present (see Figure 1).
Recent research highlighting the presence of epigenetic
modifications to the AML genome suggests that Class I and
II mutations are only one part of a more complex picture
[8, 21]. Increasingly sophisticated methods of examining the
human genome are highlighting mutations which previously
remained undetected [8]. Novel mutations in genes that are
related to epigenetic control of the genome, which encom-
passes DNA methylation (see Figures 2 and 3) and histone
modification (see Figures 4 and 5), have been found in a
significant proportion of AML patients [8]. Furthermore,
modifications to the epigenome itself, such as localized CpG
hypermethylation (see Figure 3) and global hypomethylation,
are being examined in greater depth [1, 22–24]. Many of these
mutations affecting epigenetic regulators are not regarded as
belonging to Class I or Class II, suggesting that the “two-hit
model” is no longer adequate [8]. The fact that some other
mutations occurring in AML do not have a clear class (such
as trisomy 22, which is well recognized in inv(16) leukemia
yet has an uncertain role in leukemogenesis) further indicates
that the “two-hit” theory is an oversimplification [8, 21].
Moreover, there is evidence that there is also a temporal
component to leukemogenesis; mutations have to occur at a
particular point in cell development, and in a particular order,
to allow for leukemic transformation [16, 21, 25]. This has
been reported, for example, in acute promyelocytic leukemia
(APL). The PML-RAR𝛼 fusion protein may occur at any
point in the development of the myeloid cell but is only
associated with leukemia if the translocation occurs at an
early stage when there is sufficient neutrophil elastase levels
(which reach a maximal point in promyelocytes) [25]. It is
likely, therefore, that new models for the development of
acute myeloid leukemia will become increasingly complex as
novelmutations are detected and their role in leukemogenesis
is evaluated.
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Figure 2: Figure showing methylation of cytosine residues at
CpG sites. The addition of a methyl group to convert the DNA
base cytosine to 5-methylcytosine is catalyzed by DNA methyl-
transferase (DNMT). The methyl group is transferred from S-
adenosylmethionine (SAM) to the 5-carbon position of cytosine.
4. Epigenetic Regulation of the Genome
Epigenetic regulation refers to modulation of genetic tran-
scription and expression which does not alter the genetic
code [7]. Epigenetic modifications can be transient or phys-
iologically irreversible and play key roles in developmental
patterning in the embryo [7, 26]. Following embryogenesis,
epigenetic changes continue throughout an organism’s life
[7].The twomainmechanisms of epigenetic regulation in the
cell are posttranslational histonemodifications (see Figure 4),
discussed later, and DNA methylation and hydroxymethyla-
tion, discussed below [6, 7, 24, 27].
DNA methylation is one of the key epigenetic signal-
ing methods that facilitate control of gene expression in
eukaryotic cells. Methylation patterns are known to have
crucial roles in embryonic patterning, X-inactivation, and
genomic imprinting, as demonstrated by an early lethal effect
in DNAmethyltransferase- (DNMT-) null mice [22]. Control
of gene expression is derived throughmethylation of cytosine
residues in CpG sites—regions where a cytosine residue is
adjacent to a guanine residue [8, 22]. Mammals, including
humans, show global methylation patterns, that is, methyla-
tion of genomic, transposon, and intergenic sequences [23].
Regions with a high density of CpG sites are known as CpG
islands, and these are associated with the promoter regions
of 50% of genes in humans [7, 22]. Cytosine methylation of
promoter sites is associated with recruitment of corepressor
complexes and reduced gene expression [28]. Methylation
of genes associated with maintenance of stem cell status
in hematopoietic cells, such as homeobox A9 (HOXA9)
and meis homeobox 1 (MEIS1), increases as these cells
differentiate, and demethylation occurs in genes concerned
with differentiation of specific cell lines [26].While non-CpG
island methylation is reversible, methylation of CpG islands
persists throughmitosis and is only physiologically reversible
in the embryo [7].
Hydroxylation of methylated cytosine residues is a mech-
anism by which non-CpG islandmethylation can be reversed
and is catalyzed by the enzymes encoded by the genes TET1-3.
Hydroxymethylated DNA is unable to bind to proteins that
repress transcription, thus releasing the inhibitory effect of
DNA methylation on the genome [29]. Leukemogenesis has
been associated with both hypo- and hypermethylation of
CpG islands at different loci and also with global methyla-
tion changes, although the pathological implications remain
unclear.
5. DNA Methylation and AML
It is evident that methylation patterns play a role in
altering expression of genes crucial to leukemogenesis
(see Figures 2 and 3). Figueroa et al. carried out DNAmethy-
lation profiling of 344AML samples and found that subjects
could be separated into 16 subclasses according to methyla-
tion signatures [24]. These subclasses often reflected cytoge-
netic or molecular subgroups: PML-RAR𝛼, CBF𝛽-MYH11,
and RUNX1-RUNX1T1 (AML1-ETO) were each associated
with specific methylation signatures. Specific genetic lesions
were enriched in further eight groups, while the remaining
five groups did not appear to be associated with particular
mutations. The finding that AML cases could be separated
according tomethylation signature, with some clusters highly
enriched in specific mutations (t(8;21), inv(16), t(15;17), and
11q23), has been observed in a number of studies [24, 30,
31]. Figueroa et al. found that clinical outcomes could be
predicted according to DNA methylation cluster, including
the groups without specific mutations [24]. Moreover, cases
in clusters enriched for a particularmutation, but not bearing
it themselves, shared the prognostic implications of the group
as a whole. This was seen in 9 patients classified into one
of the CBF leukemia clusters [24]. The groups that were
not associated with particular mutations may be reflecting a
shared but as yet unknown genetic lesion, or there may be
a number of mutations which result in the same epigenetic
profile. It is apparent, therefore, that epigenetic changes in
leukemic cells occur in a specific and distinct manner—
methylation patterns may vary more between subclasses of
AML than between AML and controls—and appear to be
responsive to overlying genetic mutations [30].
The group also identified a group of 45 genes which
were aberrantly methylated in the majority of AML cases
compared to normal bone marrow cells. This may reflect
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Figure 3: Methylation of CpG islands reduces gene transcription and is purported to play a role in malignancy through reduced expression
of tumor suppressors and genes concerned with differentiation. Global hypomethylation is also frequently observed in malignant cells, and
while it is likely that there is genetic instability and promotion of protooncogene expression, the exact role of global methylation patterns in
the development of cancer is uncertain.
a shared epigenetic patterning process in leukemogenesis
or the methylation profile of leukemia-permissive cells [24].
Genes coding for tumor suppressors, nuclear import proteins,
transcription factors, factors associated with apoptosis, and
a regulator of myeloid cytokines were included in the 45
genes aberrantly methylated in the AML cells [24]. This
finding has been supported by evidence from other research
groups who identified a core of hypermethylated genes which
were present in all subclasses of AML analysed [24, 30,
31]. Downregulation of gene expression was associated with
the hypermethylated genes identified in the majority of
the AML cohort. These findings indicate that perturbation
of these genes through DNA methylation is likely to be
necessary, though probably not sufficient for leukemogenic
transformation [24]. In addition to methylation of promoter
CpG islands, Akalin et al. found evidence of specific and
distinct DNAmethylation patterns in coding and noncoding
CpG residues [30], while Saied et al. found theAMLcells to be
only 2.7% less globally methylated than controls [23]. Conse-
quently, further research into DNA methylation, both global
and localized, may highlight key leukemogenic pathways that
have been overlooked by cytogenetic and molecular analysis.
5.1. DNMT3A. The finding of recurrent mutations in
enzymes associated with DNA methylation in AML cells
further indicates that aberrant epigenetic modulation of the
genome has a pathological role in leukemogenesis. Mutations
in DNMT3A (DNA methyltransferase 3A), an enzyme
concerned with de novo methylation of CpG dinucleotides,
are among the commonest somatic mutations, occurring in
15–25% of AML [8, 32, 33]. DNMT3A mutations have also
been found in MDS and MPN and remain detectable after
leukemic transformation suggesting that these mutations
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Figure 4: Histone tail modifications include methylation, acetylation, phosphorylation, ADP-ribosylation, and ubiquitination. Of these
modifications, methylation and acetylation have the most influence on chromatin structure. Histone acetylases (HATs) catalyze acetylation
of the histone tails, and histone deacetylases (HDACs) reverse acetylation. Histone methylation can involve mono-, di-, or trimethylation of
arginine and lysine residues of one of the highly conserved histone units.
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Figure 5: Transcriptionally active euchromatin has high levels of histone acetylation and enriched trimethylation of H3K4, H3K36, or H3K79
residues. Conversely, transcriptionally repressed heterochromatin is enriched in trimethylated H3K9, K3K27, and H4K20 and has reduced
histone acetylation, mediated by HDAC activity. Heterochromatinization of euchromatin loci is induced by the binding of heterochromatin
protein 1 (HP1) to methylated H3K9 and mediated by corepressor proteins such as retinoblastoma protein (pRb) and KAP1. Demethylation
of specific histone residues is mediated by a number of histone demethylase enzymes, including LSD1 and Jumonji C-domain proteins (the
latter mentioned above in relation to IDH mutations).
occur early in clonal evolution [34]. These mutations have
also been found to be associated with M4/M5 FAB subtype,
greater age, lower overall survival, and concurrent mutations
including FLT3, NPM1, and IDH-1/IDH-2 [8, 32, 35, 36].
It is currently uncertain as to whether methylation or
gene expression patterns are altered inDNMT3Amutated AML.
In vitro, missense mutations at R882 result in increased
proliferation, and mutated DNMT3A has been found to
have reduced methylation activity [37]. Murine models
demonstrate both hyper- and hypomethylation of different
loci, in addition to increased expression of genes involved
in hematopoietic stem cell self-renewal [38]. Nonmalignant
expansion of the stem cell compartment has been found
in DNMT3A knockout mice [38]. However, the role of
DNMT3A mutations in human leukemogenesis is unclear.
Ley et al. found that although DNMT3A expression, global
methylation patterns, and overall levels of methylated cyto-
sine were normal, hypomethylation at 182 loci indicated that
there may be disruption of the expression of unknown genes
in DNMT3Amutated AML [32]. Yan et al. found that both gene
expression and methylation patterns were altered, proposing
that DNMT3A mutations gave rise to hypomethylation of
HOX genes [39]. Conversely, Ribeiro et al. did not find a
strong methylation signature, although they did identify one
methylation cluster that was enriched for DNMT3A, FLT3-
ITD, and NPM1 mutations and showed increased expression
of various HOX genes [35]. This HOX overexpression may
play a role in leukemic transformation [39]. HOX genes are
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known to be involved in normal hematopoiesis and also
in leukemogenesis, with aberrant HOX expression being a
well-recognized finding in leukemic cells [40]. It is apparent,
therefore, that the role of DNMT3Amutations in the overex-
pression of certain genes, such as theHOXgenes, is uncertain,
and interactions with other somatic mutations such as NPM1
need further investigation.
While the evidence for a direct modulation of gene
expression by mutated DNMT3A is currently lacking, there
may be an indirect effect through aberrant methylation
of nonpromoter sites. DNMT3A-mediated methylation of
nonpromoter and nonproximal promoter regions was found,
unexpectedly, to increase expression of genes associated with
postnatal neurogenesis in mice, perhaps through opposition
of polycomb repression [41]. It is evident, therefore, that the
impact of DNMT3A mutations on methylation patterns and
proximal and distant control of gene expression is complex
and poorly understood.
While the exact mechanism remains obscure, it is likely
that DNMT3A mutations play a significant role in the
development of leukemogenesis. Kro¨nke et al. analyzed 53
NPM-1mutated AML cases at diagnosis and again at relapse.
Of the 5 cases of NPM-1mutated DNMT3Amutated AML where
the NPM-1 mutation was lost, the DNMT3A mutation
remained detectable [42]. Sequencing demonstrated the
same DNMT3A mutations at relapse as at first diagnosis,
suggesting that the DNMT3A dominant clone gave rise to
NPM-1mutated and wildtype subclones (and that the latter was
perhaps selected out by chemotherapy treatment) [42]. This
finding called into question the proposed role of NPM-1 as a
founder mutation, suggesting that DNMT3A mutations may
precede NPM-1 mutations. Animal experiments have shown
thatDNMT3Aknockoutmice do not developAML, however,
demonstrating the necessity of subsequent mutations in the
leukemogenic process [42]. Despite these findings, one case
in the cohort lost a DNMT3A mutation but retained the
NPM-1 mutation, indicating that the mutational sequence
is probably not particularly strict [42]. The presence of
these “foundermutations” and the requirement for secondary
genetic hits are an intriguing insight into leukemogenesis and
also suggest that total eradication of AML may be achieved
through elimination of the preleukemic clones.
In addition to a putative role in the initiation of leuke-
mogenesis, there is also evidence to suggest that mutations in
genes concerned with DNA methylation and hydroxylation
(DNMT3A, TET2, and IDH1/2) may play a role in promoting
therapy resistance and relapse.Wakita et al. found that, unlike
mutations considered to be “first hit” mutations, such as
NPM1 and CEBPA, DNMT3A mutations were always still
detectable at relapse [43]. Moreover, the early presence of
DNMT3A mutations was associated with a higher incidence
of FLT3-ITD positive clones at relapse [43]. It is possible that
mutations in epigenetic modifiers result in genetic instability
and promote both acquisition of novel FLT3-ITD mutations
and the expansion of existing FLT3-ITD positive clones [43].
However, the role of DNMT3A mutations in genetic insta-
bility is also uncertain, as a number of studies have reported
no increase in somatic mutations in DNMT3Amutated disease
compared with DNMT3Awild-type disease [32]. This would
challenge the theory that these mutations lead to significant
genetic instability. It is nonetheless likely that DNMT3A
mutations affect response to therapy, suggested by poorer out-
comes in patients treated with conventional chemotherapy
[43] and improved responses when treated with high-dose
anthracycline induction [33].
The exact association between prognosis and DNMT3A
mutations is a subject of some debate: Marcucci et al.
found that non-R882 mutations were associated with an
almost threefold increased risk of relapse or death (𝑃 =
0.002) once adjusted for mutations in NPM1, CEBPA, WT1,
and FLT3-ITD in a multivariable analysis. However, R882
mutations had no prognostic impact on patients >60 years,
with the inverse observed in younger patients [44]. This
variation in prognostic significance according to age may
reflect differences in concurrent mutations, such as changes
in incidence of ameliorating mutations such as NPM1 [44].
Although variation in prognostic impact of mutation type
in different age groups was not reported in other studies,
perhaps due to noninclusion of older patient groups, Ley et al.
and Thol et al. found that DNMT3A mutations heralded a
poorer prognosis in NPM1wildtype/FLT3-ITDmutated CN-AML
[32, 36]. Conversely, Ribeiro et al. found that DNMT3A
mutations were a particularly poor prognostic indicator
in NPM1wildtype/FLT3wildtype AML, and overall there was
still an association with a worse outcome [35]. Gaidzik’s
large study of 1770 AML patients aged 18–60 and treated
with regimens of a similar intensity found that DNMT3A
mutations were associated with a poorer prognosis in the
subgroup of patients with ELN unfavourable CN-AML [45].
An association with higher CCR rates across all classes
of AML was likely to be related to the relative rarity of
DNMT3A mutations in AML with unfavorable cytogenetics
rather than a genuine association with DNMT3A mutations
[45]. Thus, this study found that although DNMT3A had
discernible prognostic significance in a subgroup of patients
when the whole group was analyzed, the prognostic impli-
cations were masked, perhaps by cytogenetic status [45].
The evidence from this, the largest study to date, suggests
that in young patients receiving intensive treatment there
may be little role for DNMT3A as a prognostic marker,
although other studies indicate that DNMT3A mutations
could have prognostic relevance in specific patient groups
[32, 35, 36]. It is likely that there is also a distinction
between R882 and non-R882 mutations, both in terms of
biological function and prognosis, which requires further
investigation.
Interestingly, the recurrent favorable risk genetic translo-
cations, t(8;21), inv(16), and t(15;17), are rarely, if ever, seen
in conjunction with DNMT3A mutations [32]. The fact
that these genetic lesions appear to be mutually exclusive
with DNMT3A may suggest that they have similar roles in
leukemogenesis, and so the occurrence of one is unnecessary
if the other is already present. However, if this is the case, then
it is unclear why the prognostic significance of the DNMT3A
mutation is so much more adverse than the favorable risk
translocations.
Advances in Hematology 7
6. DNA Hydroxymethylation and AML
6.1. TET2. Other epigenetic modifiers that can be mutated in
AML include TET2, IDH1, and IDH2. These mutations alter
the epigenome through modulation of hydroxymethylation,
and like DNMT3A, have been found to persist in AML
from diagnosis to relapse [43]. TET 1-3 gene products are
known to modulate hydroxymethylation by catalyzing the
conversion of 5-methylcytosine to 5-hydroxymethylcytosine
[29]. Mutations in TET2 have been detected in 7–23% of
AML and in 10–20% of MPN/MDS [8, 33, 46–48]. TET2
and IDH mutations appear to be mutually exclusive. TET2
mutations have been found to occur in conjunction with
other significant mutations such as NPM1, RAR𝛼, KIT, FLT3,
RAS, MLL, and CEBP𝛼, although there is no significant
incidence-association [47–49]. Recent evidence also suggests
that TET2 mutations occur more frequently in cytogeneti-
cally normal (CN) AML and are associated with older age,
higher white blood cell counts, and lower platelet counts [48].
TET2 is found on chromosome 4q24, a breakpoint that has
been associated with several leukemia-related translocations
such as t(3;4), t(4;5), and t(4;7) [50]. TET2 mutations appear
to convey loss of function, and the majority of cases are
heterozygous forTET2mutations [8].This is supported by the
finding that TET mutant proteins in myeloid malignancies
are devoid of enzymatic function [51]. Furthermore, the
mutual exclusivity of TET2 and IDH mutations supports the
role of aberrant hydroxymethylation in leukemogenesis, as
IDH gain-of-functionmutations produce 2-hydroxyglutarate
which inhibits TET2 catalytic activity [52].
It is thought that TET2 mutations are an early event in
leukemogenesis and perhaps may even initiate the malignant
process [29, 46, 53]. TET2 mutations may arise before or
after JAK2 mutations are acquired in MPN and have also
been found to occur for the first time in MPN undergoing
leukemic transformation [47, 54]. Although the exact role
of epigenetic changes resulting from TET2 mutations in
leukemogenesis is uncertain, it is likely that TET2-mediated
hydroxymethylation plays a pleiotropic role in modulation of
self-renewal and differentiation [51, 52]. It has been observed
that TET2 loss of function leads to increased replating activity
in vitro and stem cell renewal in mice [55]. Murine models
have also demonstrated that TET2 deletion results in progres-
sive myeloproliferation, extramedullary hematopoiesis, and
expansion of undifferentiated myeloid precursors occurring
in a pattern highly reminiscent of human CMML [55]. More-
over, competitive reconstitution assays in lethally irradiated
mice showed that the cells with induced deletion of TET2
had a proliferative advantage over wildtype cells [55]. In vitro
and animal models, therefore, suggest that TET2 mutations
result in a loss of control of cell renewal at many different
points in hematopoietic differentiation [55]. This, along with
the fact that TET2 mutations are seen in a wide spectrum
of myeloid disorders in humans, suggests that loss of TET2
catalytic function may induce leukemogenesis by increasing
the self-renewal capacity of cells and potentiating acquisition
of furthermutations [51, 52, 54, 55]. Cases of AMLwith TET2
mutations also appear to have their own gene expression
signature, featuring deregulation of genes associated with
stem cell self-renewal, cell cycle control, and cytokine and
growth factor cell signaling [47]. Gaidzik et al. found that the
gene expression signature identified in TET2mutated AML was
shared by a TET2wildtype group, a large proportion of which
was comprised of IDHmutated AML [49].This finding supports
the theory that the two genemutations share common patho-
logical mechanism [49]. Interestingly, Metzeler et al. found
altered gene expression signatures in TET2 mutated AML
in the favorable risk group, but not in TET2 mutated AML
in the intermediate risk group [47]. Both groups were also
found to have differentially altered micro-RNA expression
signatures which involved various micro-RNAs implicated in
hematological malignancies and were nonoverlapping [47].
This finding indicates that TET2 has different implications for
gene and micro-RNA expression according to AML subset.
The relationship between TET2 mutations and prognosis
is unclear and different studies have shown conflicting results.
It is likely that TET2 mutations do not affect MPN prognosis
but may be a marker of better prognosis in MDS patients
[53, 56]. Prognostic implications in AML are uncertain.
Some studies, such as the relatively small study by Nibourel
et al., have found no association between prognosis and
TET2 mutation status [57]. Gaidzik et al. also detected no
prognostic implications of TET2 in a large cohort of 783
subjects [49]. Conversely, other studies, for example, those by
Abdel-Wahab et al. and Metzeler et al. both, concluded that
TET2 was linked with poorer prognosis in AML [29, 46, 47,
57, 58]. Metzeler et al. found that as well as lower response
rates and higher rates of relapse, TET2mutated subjects had
a median OS of 1.5 years, while TET2wildtype subjects had
a median OS of 3.8 years (𝑃 = 0.001). However, this
observation was limited to ELN favorable risk category CN-
AML and was not seen in ELN intermediate risk CN-AML
[47]. These findings were echoed by Weissmann et al., who
found that although OS was unchanged, EFS was reduced
in TET2 mutated ELN favourable risk CN-AML alone [48].
The disparity between these findings may be related to
differences in the cohorts studied;Metzeler et al., for example,
enrolled older subjects (age range 18–83) and only included
de novo AML [47]. By contrast, Gaidzik et al. analyzed data
from younger patients (age range 18–60) with de novo and
secondary AML [49]. The younger patient cohort is likely
to include more patients receiving intensive chemotherapy,
which may contribute to the disparate outcome data. How-
ever, this does not fully account for the disparity in results
as Nibourel et al. studied an older cohort of AML patients
yet identified no prognostic implications of TET2 mutations
[57]. It is possible that age itself plays some role in the effect of
TET2 mutations on survival, a suggestion perhaps supported
by the findings of Weissman et al., who observed shorter EFS
in TET2mutated patients below 65 years but no effect on older
individuals with a TET2 mutation [48]. The fact that many
different mutations are observed in the TET2 gene may also
contribute to the clinical variability seen in these studies—
mutations in different regions of the gene may have varying
effects on survival outcomes [48]. Thus, it is apparent that
TET2 mutations interrupt normal DNA hydroxymethylation
and have an as yet uncertain role in the development of
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leukemia. Although there is some debate concerning the
prognostic implications of TET2 mutations in AML, there
is reasonable evidence to suggest that TET2 mutations do
have an adverse effect on prognosis in some AML subgroups.
In the future, TET2 mutational status may have a role in
contributing to prognostication, particularly in favorable risk
CN-AML.
6.2. IDH1 and 2. The wildtype isocitrate dehydrogenases are
a group of NADP+ dependent enzymes which catalyze the
conversion of isocitrate to 𝛼-ketoglutarate in the Krebs cycle
and are thought to be involved in the prevention of oxidative
damage within the cell [52, 59, 60]. IDH mutations, first
identified in colorectal carcinoma and frequently found in
brain tumors, arise in approximately 15–30% of de novo
and secondary AML and around 5% MPN/MDS [52, 59,
60]. IDH mutations often occur in conjunction with NPM1
and are most common in patients with intermediate risk
cytogenetics including CN-AML [61]. IDH1 and 2 mutations
only occur together in around 0.3% of patients [52, 60, 62].
Thesemutations are typically heterozygous and occur at three
particular arginine residues—R132 in IDH1 and R172 and
R140 in IDH2. As yet, amino acid substitutions are the only
type of mutation that has been detected in the IDH genes
[59]. These mutations confer a neomorphic gain-of-function
effect, catalyzing the conversion of 𝛼-ketoglutarate to 2-
hydroxyglutarate (2-HG) [52, 63]. AML patients with IDH
mutations frequently have markedly elevated 2-HG levels
[59].
There are a number of mechanisms by which IDH
mutations may contribute to leukemic transformation. TET2
catalytic activity is dependent on 𝛼-ketoglutarate, iron, and
oxygen, meaning that IDH mutations result in loss of
TET2 function [52]. IDH1 and 2 mutations are, as men-
tioned above, mutually exclusive with TET2 mutations [33,
52]. Figueroa et al. found that there was also significant
overlap between the methylation signatures of IDHmutated
and TET2mutated AML [52]. The methylation signature of
IDHmutated AML, featuring a globally hypermethylated pat-
tern, is also distinct from other AML subtypes [52]. Many of
the gene promoters aberrantly hypermethylated in IDHmutated
AML are thought to relate to transcription factors involved in
myeloid differentiation and leukemogenesis, such as GATA
1/2 and EVI1 [52]. IDH mutations are likely to also affect
a number of TET2-independent leukemogenic pathways,
with histone demethylases numbering among other 𝛼-
ketoglutarate-dependent enzymes [59]. Histone demethylase
inhibition is thought to promote DNA methylation and
so may contribute to the epigenetic derangement seen in
leukemia [59]. Moreover, it is thought that high levels of the
putative oncometabolite, 𝛼-ketoglutarate, may increase the
production of reactive oxygen species and lead to increased
DNA damage [59]. It is probable that any variance between
the molecular and clinical characteristics of TET2mutated
AML and IDHmutated AML is related to aberrancies in these
additional pathways which are unaffected in TET2 mutation
[8, 59].
The impact of IDH mutations on prognosis is uncertain,
with some recent studies reporting an improved outcome
[33, 64, 65], and others reporting an inferior outcome to IDH
wildtype AML [65–67]. Other studies suggest that there is
no impact on response to therapy or survival [64, 68]. A
meta-analysis conducted by Feng et al., including 15 studies
and data from a total of 8121 AML patients, concluded that
IDH mutations are likely to have an adverse prognostic
impact overall [69]. When the disease is stratified according
to genotype, cytogenetics, and type of mutation, however,
the implications of IDH mutations are unclear. Paschka
et al. found in their study of 805AML patients that IDH
mutations predicted reduced relapse-free and overall survival
in favorable risk NPM1mutated/FLT3-ITDwildtype AML (5-year
OS was 41% compared with 65% in IDHwildtype patients
(𝑃 = 0.03)) [60], a finding replicated by Marcucci et al.
[66]. Conversely, Patel et al. found that a favorable outcome
associated with NPM1 mutations was only present when
there were concurrent IDH mutations [33]. Furthermore,
there may be differing prognostic implications according to
the particular IDH mutation that is present—IDH2 R140 is
thought to be associated with a good prognosis, while R172 is
associated with a poor outcome [33, 70]. Differences between
studies may reflect size of population studied, variation in
therapeutic regimen, inclusion criteria (such as inclusion of
de novo or secondary AML), and sensitivity of mutation
detection techniques.There may also be difficulties analyzing
data if there are variations in the prevalence of different
mutational subtypes; for example, Thol et al. combined data
for R140 and R172 mutations as only 3 subjects were found to
bear the R172 mutation [68].
Finally, the fact that virtually all IDH mutations are
detected at diagnosis, rather than arising later in the disease
process, suggests that these mutations occur very early in
leukemogenesis and are candidates as disease initiators [54,
71]. Increased acquisition of IDH mutations in advanced
MPN and MDS and in secondary AML indicates that they
may be involved in leukemic transformation [46, 54, 71].
Thus, IDHmutations appear to play a role in triggering leuke-
mogenesis and may offer a useful biomarker of disease in the
form of 2-hydroxyglutarate. Further research is required to
reliably ascertain the impact of IDHmutations on prognosis.
7. Histone Modifications in AML
Histone tail modifications play a key role in epigeneticmodu-
lation of gene expression andmay includemethylation, acety-
lation, phosphorylation, ADP-ribosylation, and ubiquitina-
tion (see Figure 4) [27, 72]. Mechanisms of aberrant histone
modification in AML include mutations in genes concerned
with polycomb group complexes (PcG), widely considered
to be the “bridge” between histone modification and DNA
methylation [72, 73]. PcGs maintain stable and heritable
transcriptional repression in specific target genes [72]. PcGs
are related to body patterning, stem cell renewal, and they
alsomay have pathogenic roles to play in oncogenesis [72, 73].
Genes coding for components of the PcG may be amplified
or overexpressed, or the PcG may be “ectopically recruited”
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to nontarget genes in cancer development [72]. Mutations
have been detected in a number of PcG components in
myeloid disorders, with some, unexpectedly, conferring a loss
of function [27, 73–76].
7.1. EZH2. Enhancer of zeste homologue 2 (EZH2)mutations
has been detected in approximately 7% of MDS, 3–13%
MPN, and occasionally in AML [8, 75–77]. EZH2 is the
catalytic component of PcG Repressor Complex 2 (PRC2),
a highly conserved H3K27 methyltransferase [6, 8, 76]. Two
further subunits, EED and SUZ12, comprise the PRC2 unit
[6, 8]. Methylation of H3K27 leads to the recruitment of
PRC1, followed by DNMT binding via EZH2 and consequent
DNA methylation [75]. EZH2 can also interact with HDACs
through EED and in this manner influences histone deacety-
lation and may exert further influence over the genome
through interaction with noncoding RNA [75]. This results
in promotion of chromatin condensation and suppression of
genes concerned with cell fate decisions, thereby influencing
stem cell renewal capacity [6].
Overexpression of EZH2 has been detected in various
epithelial malignancies, and, more recently, activating muta-
tions of EZH2 have been found in diffuse large B cell lym-
phoma [77]. It is likely that gain-of-function EZH2mutations
result in reduced expression of regulatory genes, such as
BRCA-1 and p16, and increased activity of cellular pathways
concerned with proliferation and invasion [75]. Overexpres-
sion of EZH2 bestows unlimited replicative potential on
hematopoietic stem cells in vitro and prevents stem cell
exhaustion following repeated serial transplants in irradiated
mice [74]. Unexpectedly, missense, nonsense, and frameshift
mutations have been found in MDS, MPN, and AML [6, 76,
77]. These mutations frequently result in a truncated SET
domain, thought to be crucial to the catalytic activity of the
protein [76]. These findings suggest that the loss-of-function
mutations in EZH2 may contribute to myeloid neoplasm
[6, 76, 77]. The oncogenic implications of both loss and gain
of function of EZH2 implies dual, tissue-specific roles as both
oncogene and tumor suppressor [6, 8, 77]. Mutations in EED
and SUZ12 rarely occur in patients with MDS/MPN overlap
disorders or PMF but may occur in conjunction with EZH2
[76].
EZH2 mutations have been detected in patients with
refractory anemia, a relatively early stage of MDS, and have
been found to remain constant as the disease progresses
towards secondary AML [76]. It is likely, therefore, that this
is an early event in myeloid disease and not an initiator of
leukemic transformation. EZH2 is located on chromosome
7q, and loss of this chromosome in MDS has long been
recognized as a poor prognostic indicator [76, 77]. Further
research has found that it is likely that this poor prognosis
in these patients is associated with loss of EZH2 [75, 78, 79].
The prognostic implications of EZH2 mutations in AML
have been more elusive, largely due to the low incidence of
these mutations in de novo disease. Wang et al. identified
EZH2 mutations in 1.7% of 714 subjects with de novo AML,
amounting to 13 patients, and were unable to identify any
association with OS, EFS, or chance of CR [79].The relevance
of this observation to AML in general, however, is limited
considering the small number of subjects bearing EZH2
mutations. The apparent role of the various EZH2 mutations
in oncogenesis is an insight into the complex function of
PRC2 as an epigenetic regulator.
7.2. ASXL-1. Somatic nonsense, missense, frameshift, and
pointmutations of the additional sex combs-like gene (ASXL-
1) are found in 10–25%MDS, 10–15%MPN, and 5–30% AML
[6, 71, 80, 81]. These mutations are more frequently found
in secondary than de novo AML and occur in about 45%
of CMML [82]. The majority of mutations cause frameshift
and mostly occur in the PHD domain, which is thought
to be responsible for methylated lysine binding [73, 83]. It
is unclear whether ASXL-1 mutations confer a loss or gain
of function—however, evidence from Abdel-Wahab et al.
suggests that a large proportion of these mutations results in
reduced ASXL-1 expression [73]. It is thought that ASXL-1
exerts a modulatory effect on the epigenome through both
activating and suppressive interactions with PcGs (partic-
ularly PRC2) and trithorax genes [73, 80]. Consequently,
loss of ASXL-1 expression in myeloid neoplasm appears
to result in reduced H3K27me3 concentrations at specific
target loci, perhaps through inhibition of PRC2 recruitment,
and consequent overexpression of leukemia-promoting genes
[73]. Wildtype ASXL-1 may also interact with BAP-1 to
form a deubiquitinase specific to H2AK119 which results in
repression of gene transcription [80]. Mutations in ASXL-1
may also, therefore, affect epigenetic regulation through
interruption of ubiquitin removal from specific histone lysine
residues, although the relationship with leukemogenesis
is unclear [84]. Furthermore, alteration of the epigenome
through uncontrolled expression of posterior HOX genes
is thought to be an additional consequence of ASXL-1
mutations [73, 84]. ASXL-1 appears to have a role in both
repressing and promoting HOX gene expression in mice
and flies [85]. Findings from murine knockout models have
been controversial, with some researchers reporting only
mild myeloerythroid lineage defects and others finding an
MDS/MPN-like phenotype, particularly if there is concurrent
RAS mutation [73, 85].
ASXL-1 mutations are frequently detected at diagnosis
of MDS and MPN and remain constant throughout disease
progression [46]. Despite one study which found increased
mutation incidence in myelofibrosis secondary to other
MPNs, evidence suggests that ASXL-1 mutations are early
eventswhichmayprecede JAK2 andTET2mutations [46, 73].
ASXL-1 mutations—particularly frameshift—are associated
with more aggressive disease, faster time to leukemic trans-
formation and shorter overall survival in MPN and MDS
[71, 81]. The prognostic implications of ASXL-1 mutations
in AML are less clear. Some studies have found that, like
TET2,ASXL-1mutations confer a particularly poor prognosis
in ELN favorable AML [97]. However, one large study by
Shen et al. reported no association with outcome overall
but reduced survival in the intermediate risk group [98].
Similarly, Pratcorona et al. found that there was a significant
association with poorer survival and ASXL-1 mutations
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Table 1: Key genetic mutations thought to have implications for prognosis in AML.The genetic mutations included in the table are reviewed
below. Table compiled with information from [29, 32, 35, 39, 50, 52, 58, 61, 66, 67, 73, 76, 80, 86–96].
Gene Mutation type Mutation frequency Consequence ofmutation Prognostic implications Initiating lesion
DNMT3A
Mainly missense
60% at R882
Often heterozygous
15–25% AML
R882 mutations reduce
binding affinity and
catalytic activity—LOF
Likely poorer prognosis.
Affected by
R882/non-R882, CM,
patient age Adverse
prognosis in intermediate
risk AML
Uncertain
TET2
46% frame shift
Also missense, nonsense,
and splice site variations
Majority heterozygous
7–23% AML
10–20%MPN/MDS
Truncated protein and
consequent reduction in
hydroxymethylation—
LOF∗
Poorer prognosis in
favorable risk CN-AML
No effect in MPN, possibly
improved prognosis in
MDS
Early event,
possibly initiating
IDH1 + 2
Amino acid substitutions
R132 (IDH1)
R172, and R140 (IDH2)
Heterozygous
15–30% AML
5%MPN/MDS
Neomorphic gain of
function
Production of 2-HG,
inhibition of TET2
function
Unclear—R140Q may have
favorable effect on
prognosis R132H/R172K
may have no effect
However some studies
suggest IDH mutations
have adverse impact on
favorable CN-AML
NPM1mut/IDHmut AML has
a favorable outcome
Early event,
possibly initiating
ASXL1 Nonsense, missense, frameshift, and point mutations
10–15% MPN/AML
10–25% MDS
Uncertain if function
lost or gained—research
suggests reduced ASXL1
expression
Poor prognostic marker in
AML and MPN
Very early,
increased leukemic
progression in
MPN
EZH2 Missense, nonsense, andframe shift
Occasional in AML
MDS 7%
MPN 3–13%
Truncated SET
domain—LOF
Gain of function
observed in other
malignancies
Worse OS in MDS, CMML,
and PMF
(del)7q poor prognostic
indicator in
MDS—probably in part
due to loss of EZH2
Very early event in
MPN, probably not
leukemic initiator
∗LOF: loss of function.
which was particularly evident in the intermediate risk group
but was also found overall [82]. Chou et al. found in a
cytogenetically heterogeneous cohort that although ASXL-1
mutations were not significant predictors of prognosis in
a multivariate analysis, they were associated with lower
CR and OS [99]. Conversely, Schnittger et al. investigated
intermediate risk patients and found that although there was
a strong correlation between occurrence of ASXL-1mutated
and mutations with adverse prognostic implications (such
as RUNX-1), ASXL-1 mutations remained an independent
adverse risk factor [83]. The cytogenetically homogeneous
nature of the study population supports the authors’ finding
that ASXL-1 is an adverse prognostic indicator in ELN
intermediate risk AML. It is likely, therefore, that ASXL-1
mutations represent an independent risk factor for poor
survival in particular genetic groups and perhaps in different
age groups. The evidence suggests that ASXL-1 mutations
have prognostic implications in MDS, MPN, and some
categories of AML and perhaps in AML overall [80, 82, 99].
Although not yet fully understood, the apparent role of EZH2
and ASXL-1 mutations in leukemogenesis is indicative of
the significance of PRC2-mediated epigenetic modifications
in normal and leukemic hematopoiesis.
8. Conclusion
Recent DNA sequencing studies have facilitated the iden-
tification of a hitherto unrecognized class of genetic muta-
tions in AML—mutations in epigenetic modifying genes
(see Table 1). The occurrence of mutations in epigenetic
modifiers in AML highlights the inadequacy of the “two-
hit model” as a mechanistic explanation of leukemogene-
sis. Mutations in genes concerned with regulation of the
epigenome potentially offer a valuable insight into the process
of leukemogenesis. These mutations also contribute to the
existing body of knowledge that aids risk stratification of
AML throughmolecular and cytogenetic analysis of leukemic
cells. Mutations in genes such as TET2, DNMT3A, and
ASXL-1 may be associated with a poor prognosis and as such
may represent a novel subset of high riskAMLwhich requires
more aggressive treatment. The prognostic implications of
IDH 1 and 2, and EZH2 mutations are unclear. There is
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considerable debate about the prognostic implications of
various genetic mutations in AML, in part due to the fact
that direct comparison between studies is difficult, if not
impossible. Patient cohorts frequently vary according to age,
type and intensity of therapy, and inclusion of different AML
subtypes (e.g., all AML compared with CN-AML). Studies
may also vary in their methodology, such as in differences
in the subgroup analysis performed or the proportion of
patients selected for analysis, which if low (e.g.,Marcucci et al.
and Ribeiro et al. only analysed 18% and 13% of their cohort
resp.) [35, 44] has the potential to introduce an element of
selection bias.
Identifying the prognostic implications of a single muta-
tion holds many challenges for researchers. There are many
factors which may alter prognosis in AML, and these factors
may influence study results to different degrees. Grimwade
et al. found that, as well as cytogenetic groups, the response
to first course of chemotherapy was a significant prognostic
indicator [1, 10]. There are a number of other indicators of
prognosis, such as age, race, and performance status. White
cell count, platelet count, LDH level, and bilirubin may also
predict outcome [1, 4, 10]. It is likely that there is interplay
between different prognostic factors; for example, Leith et al.
found that elderly AML sufferers had increased expression of
a multidrug resistance protein (MDR1) and high functional
drug efflux, aswell as a higher rate of unfavorable cytogenetics
[100]. Thus, there are many variables which may alter out-
come in AML other than genetic and cytogenetic mutations.
Nonetheless, clearer definition of unfavorable molecular
profiles may help determine treatment; Patel et al. identified
a subgroup of AML patients with particular mutations who
benefited from an increased dose of daunorubicin [33].While
previously only favorable risk patients have been shown to
benefit from intensified dose chemotherapy, individuals with
unfavorable DNMT3A and MLL-PTD mutations (as well as
the favorable NPM1) had improved responses [33]. These
findings fromPatel et al. suggest that incorporating data from
more extensive mutational analyses can improve prognostic
stratification [33]. Improved classification of AML based on
molecular genetics as well as cytogeneticsmay also, therefore,
yield improved outcomes.
Despite a rapidly growing base of knowledge concerning
genetic mutations in AML, relatively few therapeutic options
have arisen.This may change with a greater understanding of
mutations in genes concerned with epigenetic modifications.
The identification of novel mutations in AML may highlight
putative drug targets; the neomorphic gain-of-function effect
observed in IDH1 and 2 mutations is a potential target for
enzyme inhibition, for example. Equally, the reversible nature
of epigenetic modifications has led to hopes that treatments
such as DNMT and histone deacetylase inhibitors may
represent a valuable addition to the therapeutic arsenal in
AML [6, 7].These drugs have been used with some success in
MDS and AML, particularly in elderly populations unable to
undergo intensive chemotherapy regimens [101–105]. Further
research into the role of epigenetic aberrations in leuke-
mogenesis may inform the development of targeted histone
deacetylase inhibitors and personalized treatment regimens.
Furthermore, study of mutations occurring in epigenetic
modifying genes has identified potential biomarkers, such
as 2-HG in IDHmutated AML, which may reflect response to
therapy and act as an early indicator of relapse [106].
Overall, therefore, the recent identification of mutations
in genes with epigenetic function has added to the under-
standing of leukemia pathogenesis and identified potential
therapeutic targets. Identification of mutations in other
classes of genes, such as those concerned with cell adhesion
and the spliceosome, in addition to elucidation of the role
of micro-RNAs in AML, is likely to further inform prog-
nostic and therapeutic decision making and understanding
of the leukemogenic process. Indeed, it is clear from recent
advances that whole genome or targeted exome sequencing
has the potential to improve treatment strategies and thereby
survival rates in AML, and in the future it may play an
important role in the clinical workup of every patient with
AML to facilitate more effective personalized therapy.
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